Stockscreener 앱 받기
224.60
1.77%
-4.05
시장 영업 전:
224.31
-0.29
-0.13%
전일 마감가:
$228.65
열려 있는:
$225.76
하루 거래량:
1.54M
Relative Volume:
0.97
시가총액:
$30.05B
수익:
$4.29B
순이익/손실:
$577.22M
주가수익비율:
53.37
EPS:
4.2086
순현금흐름:
$641.34M
1주 성능:
+3.51%
1개월 성능:
-16.03%
6개월 성능:
-32.47%
1년 성능:
-49.97%
1일 변동 폭
$222.12
$227.99
1주일 범위
$216.50
$228.98
52주 변동 폭
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
224.60 | 30.60B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Familial Amyloid Polyneuropathy Market - Future Market Insights
ALNY Looks 56.7% Undervalued on GF Value™ - GuruFocus
Alnylam Pharmaceuticals (ALNY): Investor Outlook With A 62.82% Potential Upside - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
S&CO Inc. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing - The Motley Fool
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Kessler Topaz Meltzer & Check, LLP Encourages Alnylam - GlobeNewswire
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The AI Journal
ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256 - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company - MarketBeat
S&P 500 Futures Climb In Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead - Moomoo
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test - simplywall.st
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318 - Moomoo
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)? - simplywall.st
Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Drugs that missed the mark in pharma’s last earnings round - Pharma Voice
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Aug 2026 $ALNY - marketbeat.com
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - benzinga.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring a 71% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
PensionDanmark Pensionsforsikringsaktieselskab Sells 12,119 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Pacer Advisors Inc. Sells 5,110 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Has $46.87 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock forecasts - Yahoo Finance UK
Research Analysts Offer Predictions for ALNY Q3 Earnings - MarketBeat
ALNYLAM PHARMACEUTICALS INC (1ALNY.MI) stock price, news, quote and history - Yahoo Finance Singapore
Empowered Funds LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation - simplywall.st
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Truist Financial Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Securities Fraud Investigation into Alnylam - GlobeNewswire
Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story? - simplywall.st
Quantinno Capital Management LP Purchases 8,258 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
Barclays Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $450.00 - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: 87.96% Potential Upside Beckons Investors - DirectorsTalk Interviews
ALNYLAM PHARMACEUTICALS INC : RAYMOND JAMES CUTS TARGET PRICE TO $420 FROM $468 - webull.com
Cetera Investment Advisers Has $7.67 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation - ChartMill
Alnylam (ALNY) Stock Stalls As TTR Sales Top $1b And Guidance Tightens - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $350.00 at Oppenheimer - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - finance.yahoo.com
Alnylam Earnings: Shares Tank Amid Reduced Outlook for Key ATTR Franchise - Morningstar
Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highl - GuruFocus
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
3.70%
자본화:
|
볼륨(24시간):